Literature DB >> 33563480

Drug Repurposing for Rare Diseases.

Helen I Roessler1, Nine V A M Knoers2, Mieke M van Haelst3, Gijs van Haaften4.   

Abstract

Currently, there are about 7000 identified rare diseases, together affecting 10% of the population. However, fewer than 6% of all rare diseases have an approved treatment option, highlighting their tremendous unmet needs in drug development. The process of repurposing drugs for new indications, compared with the development of novel orphan drugs, is a time-saving and cost-efficient method resulting in higher success rates, which can therefore drastically reduce the risk of drug development for rare diseases. Although drug repurposing is not novel, new strategies have been developed in recent years to do it in a systematic and rational way. Here, we review applied methodologies, recent accomplished progress, and the challenges associated in drug repurposing for rare diseases.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Keywords:  drug discovery; drug repositioning; drug repurposing; genetic diseases; rare diseases

Year:  2021        PMID: 33563480     DOI: 10.1016/j.tips.2021.01.003

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  18 in total

Review 1.  Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices.

Authors:  Tushar Saha; Miguel E Quiñones-Mateu; Shyamal C Das
Journal:  Int J Pharm       Date:  2022-07-20       Impact factor: 6.510

2.  Drugs and biologics receiving FDA orphan drug designation: an analysis of the most frequently designated products and their repositioning strategies.

Authors:  Kathleen L Miller; Selma Kraft; Abraham Ipe; Lewis Fermaglich
Journal:  Expert Opin Orphan Drugs       Date:  2022-03-01       Impact factor: 1.041

Review 3.  How can natural language processing help model informed drug development?: a review.

Authors:  Roopal Bhatnagar; Sakshi Sardar; Maedeh Beheshti; Jagdeep T Podichetty
Journal:  JAMIA Open       Date:  2022-06-11

4.  Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases.

Authors:  Anup P Challa; Nicole M Zaleski; Rebecca N Jerome; Robert R Lavieri; Jana K Shirey-Rice; April Barnado; Christopher J Lindsell; David M Aronoff; Leslie J Crofford; Raymond C Harris; T Alp Ikizler; Ingrid A Mayer; Kenneth J Holroyd; Jill M Pulley
Journal:  Front Genet       Date:  2021-07-28       Impact factor: 4.599

5.  Untreated PKU patients without intellectual disability: SHANK gene family as a candidate modifier.

Authors:  K Klaassen; M Djordjevic; A Skakic; B Kecman; R Drmanac; S Pavlovic; M Stojiljkovic
Journal:  Mol Genet Metab Rep       Date:  2021-11-19

6.  Discovery of a functionally selective ghrelin receptor (GHSR1a) ligand for modulating brain dopamine.

Authors:  J D Gross; D W Kim; Y Zhou; D Jansen; L M Slosky; N B Clark; C R Ray; X Hu; N Southall; A Wang; X Xu; E Barnaeva; W C Wetsel; M Ferrer; J J Marugan; M G Caron; L S Barak; K Toth
Journal:  Proc Natl Acad Sci U S A       Date:  2022-03-03       Impact factor: 12.779

7.  The Research Landscape of Multiple Endocrine Neoplasia Type 1 (2000-2021): A Bibliometric Analysis.

Authors:  Chenzhe Feng; Haolin Chen; Leyi Huang; Yeqian Feng; Shi Chang
Journal:  Front Med (Lausanne)       Date:  2022-04-08

8.  Drugs and Epigenetic Molecular Functions. A Pharmacological Data Scientometric Analysis.

Authors:  Dario Kringel; Sebastian Malkusch; Jörn Lötsch
Journal:  Int J Mol Sci       Date:  2021-07-06       Impact factor: 5.923

9.  Transcriptome-Guided Drug Repurposing for Aggressive SCCs.

Authors:  Roland Zauner; Monika Wimmer; Sonja Dorfer; Michael Ablinger; Ulrich Koller; Josefina Piñón Hofbauer; Christina Guttmann-Gruber; Johann W Bauer; Verena Wally
Journal:  Int J Mol Sci       Date:  2022-01-17       Impact factor: 5.923

Review 10.  Contribution of Human Pluripotent Stem Cell-Based Models to Drug Discovery for Neurological Disorders.

Authors:  Alexandra Benchoua; Marie Lasbareilles; Johana Tournois
Journal:  Cells       Date:  2021-11-24       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.